NasdaqGS - Nasdaq Real Time Price ? USD Accolade, Inc. (ACCD) Follow Compare 3.1500 -0.0500 (-1.56%) At close: November 4 at 4:00 PM EST 3.1500 0.00 (0.00%) Pre-Market: 8:00 AM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Accolade And 2 Other Penny Stocks To Watch On US Exchanges As major U.S. indexes experience a downturn, driven by disappointing earnings reports from big tech companies, investors are exploring alternative opportunities in the market. Penny stocks, often representing smaller or newer companies, continue to attract attention despite their vintage label. These stocks can offer surprising value and growth potential when backed by strong financials, making them an intriguing option for those seeking under-the-radar investment opportunities. Simply Wall St. ? 4 days ago ACCD -1.56% PLX ARAY Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Accolade (ACCD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? 12 days ago ACCD -1.56% Accolade Welcomes Renalogic to Trusted Partner Ecosystem Accolade, Inc. (Nasdaq: ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions. PR Newswire ? 21 days ago ACCD -1.56% Accolade (ACCD) Upgraded to Buy: Here's What You Should Know Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 25 days ago ACCD -1.56% Accolade Second Quarter 2025 Earnings: Beats Expectations Accolade ( NASDAQ:ACCD ) Second Quarter 2025 Results Key Financial Results Revenue: US$106.4m (up 9.8% from 2Q 2024... Simply Wall St. ? 27 days ago ACCD -1.56% Accolade Inc (ACCD) Q2 2025 Earnings Call Transcript Highlights: Strong Revenue and Cash Flow ... Accolade Inc (ACCD) surpasses revenue expectations and maintains a robust cash position, while navigating market pressures and strategic challenges. GuruFocus.com ? 27 days ago ACCD -1.56% Q2 2025 Accolade Inc Earnings Call Q2 2025 Accolade Inc Earnings Call Thomson Reuters StreetEvents ? 27 days ago ACCD -1.56% ATGE Accolade's Q2 Boost: Revenue Rises, Losses Shrink, And Profitability Looms Personalized healthcare company Accolade Inc (NASDAQ:ACCD) stock is trading slightly higher after the company announced fiscal second quarter 2025 results. The company reported a revenue increase of 10% to $106.36 million, beating the consensus of $105.01 million. Loss per share of $0.30 beat the consensus loss of $0.44. Adjusted gross profit rose 17% Y/Y to $50.30 million. Adjusted EBITDA loss narrowed to $2.83 million from $8.76 million a year ago. As of August 31, ACCD’s cash and cash equival Benzinga ? 28 days ago ACCD -1.56% Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates Accolade (ACCD) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 28 days ago ACCD -1.56% Accolade shares soar on narrower quarterly loss, margin growth Investing.com -- Shares in Accolade Inc (NASDAQ:ACCD) jumped after the company reported a narrower-than-expected loss and strong margin growth for the fiscal Q2 2025. Investing.com ? 28 days ago ACCD -1.56% Accolade: Fiscal Q2 Earnings Snapshot SEATTLE (AP) — Accolade, Inc. (ACCD) on Tuesday reported a loss of $23.9 million in its fiscal second quarter. The Seattle-based company said it had a loss of 30 cents per share. The results beat Wall Street expectations. Associated Press Finance ? 28 days ago ACCD -1.56% Accolade Announces Results for Fiscal Second Quarter 2025 SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. “As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families GlobeNewswire ? 28 days ago ACCD -1.56% With 74% ownership, Accolade, Inc. (NASDAQ:ACCD) boasts of strong institutional backing Key Insights Given the large stake in the stock by institutions, Accolade's stock price might be vulnerable to their... Simply Wall St. ? last month ACCD -1.56% Accolade to Announce Fiscal Second Quarter 2025 Financial Results SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/B GlobeNewswire ? last month ACCD -1.56% One of the largest blockchain fund of funds has raised over $135 million across two new vehicles Accolade has invested in top crypto venture firms from a16z to Haun. Fortune ? last month ACCD -1.56% All You Need to Know About Accolade (ACCD) Rating Upgrade to Buy Accolade (ACCD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zacks ? 2 months ago ACCD -1.56% Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so t GlobeNewswire ? 2 months ago ACCD -1.56% First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies Celeste Health Solutions (Celeste), a new company that will focus on merging the power of data insights, technology and personalized health management, is being introduced to the market to simplify healthcare access for employees while also easing the burden for employers. PR Newswire ? 2 months ago ACCD -1.56% Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase SEATTLE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston on Wednesday, August 14 at 12:00 pm ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare GlobeNewswire ? 2 months ago ACCD -1.56% Why You Should Retain Xerox (XRX) in Your Portfolio Now Xerox's (XRX) bottom line is benefiting from "Project Own It," an enterprise-wide transformation initiative aimed at increasing productivity and operational efficiency. Zacks ? 3 months ago ACCD -1.56% ALYAF Performance Overview Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ACCD S&P 500 YTD -73.77% +19.77% 1-Year -56.61% +31.07% 3-Year -92.14% +22.57%
